M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
Marco Valgimigli,Giuseppe Biondi-Zoccai,Matteo Tebaldi,Arnoud W J van 't Hof,Gianluca Campo,Christian W. Hamm,Jurriën M. ten Berg,Leonardo Bolognese,Francesco Saia,Gian Battista Danzi,Carlo Briguori,Ertan Okmen,Spencer B. King,David J. Moliterno,Eric J. Topol +14 more
TL;DR: Tirofiban administration reduces mortality, the composite of death or MI and increases minor bleedings when compared with placebo and no such trend persisted at medium-term follow-up or when appraising studies testing tiroFiban at 25 microg/kg bolus regimen.
Journal ArticleDOI
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
Marco Valgimigli,Marco Borghesi,Matteo Tebaldi,Pascal Vranckx,Giovanni Parrinello,Roberto Ferrari +5 more
TL;DR: It is suggested that optimal duration of DAPT may be stent-specific and it does not support a clear association between stent potency and vulnerability to shorter DAPt therapy.
Journal ArticleDOI
Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention†
Marzia Lotrionte,Giuseppe Biondi-Zoccai,Pierfrancesco Agostoni,Antonio Abbate,Dominick J. Angiolillo,Marco Valgimigli,Claudio Moretti,Emanuele Meliga,Thomas Cuisset,Marie-Christine Alessi,Gilles Montalescot,Jean-Philippe Collet,Germano Di Sciascio,Ron Waksman,Luca Testa,Giuseppe Sangiorgi,Antonio Laudito,Gian Paolo Trevi,Imad Sheiban +18 more
TL;DR: A high clopidogrel loading dose (>300 mg) significantly reduces early ischemic events in patients scheduled for percutaneous coronary intervention andMeta-regression disclosed a significant interaction between event rate and the benefits of high loading doses, suggesting that the greater the underlying risk, the more the favorable impact of a high loading dose.
Journal ArticleDOI
Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry.
Marco Valgimigli,Francesco Saia,Paolo Guastaroba,Alberto Menozzi,Paolo Magnavacchi,Andrea Santarelli,Francesco Passerini,Pietro Sangiorgio,Antonio Manari,Fabio Tarantino,Massimo Margheri,Alberto Benassi,Massimo Giuseppe Sangiorgi,Stefano Tondi,Antonio Marzocchi,R Investigators +15 more
TL;DR: In patients undergoing angioplasty for acute myocardial infarction, transradial treatment is associated with decreased 2-year mortality rates and a reduction in the need for vascular surgery and/or blood transfusion compared with transfemoral intervention.
Journal ArticleDOI
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Gianluca Campo,Luca Fileti,Nicoletta De Cesare,Emanuele Meliga,Alessandro Furgieri,Filippo Russo,Salvatore Colangelo,Salvatore Brugaletta,Roberto Ferrari,Marco Valgimigli,R Investigators +10 more
TL;DR: Poor response to clopidogrel is an independent predictor of periprocedural myocardial infarction and worse 1-year outcome in low-risk patients undergoing PCI, whereas poor response to aspirin failed to predict a worse outcome.